Opinion|Videos|February 20, 2025
Metastatic Breast Cancer Treatment Guidelines and the Nuances of HER2-Low Disease in Clinical Practice
Panelists discuss how the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines for HER2-negative breast cancer (BC) have evolved to recognize HER2-low (IHC 1+ or 2+/ISH-negative) and HER2-ultra low (IHC 0) as distinct categories. These classifications, particularly HER2-low, guide eligibility for targeted therapies such as trastuzumab deruxtecan, expanding treatment options beyond traditional chemotherapy for previously categorized HER2-negative patients.
Advertisement
Episodes in this series
Video content above has been prompted by the following:
- How do the NCCN and ASCO/CAP guidelinesguide the treatment of HER2-negative BC, and how do the concepts of HER2-low and HER2-ultra low disease impact clinical decision-making?
Advertisement
Related to this article
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
After initial breast cancer treatment, pharmacists can help patients navigate ongoing endocrine therapy, manage persistent adverse effects, and address medication concerns that affect long-term care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5